Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Within TriLink, discovery mRNA revenue increased 17% year over year, supported by demand from larger preclinical programs. Maravai said it recorded no COVID-related GMP revenue in the second quarter. Adjusted loss per share was $0.02, compared with $0.08 in the prior-year period. The company continues to expect TriLink revenue to grow in the high teens and Cygnus revenue to rise at a low- to mid-single-digit rate.